First blood test for the early detection of lung cancer.

Lung cancer is the deadliest cancer of all, and it is usually due to late detection. COVID is making it worse and its impact will cause many more deaths than estimated in the next five years.

SABARTECH has been fighting for three years to reverse this situation with the introduction of the EarlyCDT-Lung test in the Spanish Health System.

What is EarlyCDT- Lung?

EarlyCDT-Lung uses our body’s own immune response to measure blood levels of 7 autoantibodies that are commonly generated in response to lung cancer.

It can detect any type of lung cancer and from early stages.

How does EarlyCDT- Lung work?

EarlyCDT-Lung is fast and convenient.

The physician requests a serum sample obtained from a simple blood draw at any blood collection centre and asks for the sample to be collected.

It is done using a simple enzyme-linked immunosorbent assay (ELISA),  now available for any hospital laboratory in Spain and Sabartech’s laboratory.

What is the application of EarlyCDT- Lung?

As a pre-scan test prior to other diagnostic imaging techniques such as chest X-ray (CXR) or computerized axial tomography (CAT) in a population considered to be at high risk of lung cancer.

As a post-scan test to confirm the risk of malignancy in patients who have a solitary pulmonary nodule (SPN) detected on the chest scan. Most SPNs are benign and are often found by chance on any other X-ray or CT scan.